WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 202370
CAS#: 382180-17-8
Description: Pyroxamide is a synthetic derivative of hydroxamic acid with antineoplastic properties, Pyroxamide inhibits histone deacetylases involved in transcription; induces hyperacetylation of core histones, modulating chromatin structure and affecting transcription of some genes that inhibit tumor growth; and induces growth arrest and apoptosis. Pyroxamide is used in clinical studies for cancer chemotherapy.
MedKoo Cat#: 202370
Name: Pyroxamide
CAS#: 382180-17-8
Chemical Formula: C13H19N3O3
Exact Mass: 265.14264
Molecular Weight: 265.31
Elemental Analysis: C, 58.85; H, 7.22; N, 15.84; O, 18.09
Synonym: Pyroxamide.
IUPAC/Chemical Name: N1-hydroxy-N8-(pyridin-3-yl)octanediamide
InChi Key: PTJGLFIIZFVFJV-UHFFFAOYSA-N
InChi Code: InChI=1S/C13H19N3O3/c17-12(15-11-6-5-9-14-10-11)7-3-1-2-4-8-13(18)16-19/h5-6,9-10,19H,1-4,7-8H2,(H,15,17)(H,16,18)
SMILES Code: O=C(NO)CCCCCCC(NC1=CC=CN=C1)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not soluble in water.
Shelf Life: >5 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 265.31 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Einsiedel HG, Kawan L, Eckert C, Witt O, Fichtner I, Henze G, Seeger K. Histone deacetylase inhibitors have antitumor activity in two NOD/SCID mouse models of B-cell precursor childhood acute lymphoblastic leukemia. Leukemia. 2006 Aug;20(8):1435-6. Epub 2006 Jun 29. PubMed PMID: 16810202.
2: Kouraklis G, Theocharis S. Histone deacetylase inhibitors: a novel target of anticancer therapy (review). Oncol Rep. 2006 Feb;15(2):489-94. Review. PubMed PMID: 16391874.
3: Kutko MC, Glick RD, Butler LM, Coffey DC, Rifkind RA, Marks PA, Richon VM, LaQuaglia MP. Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro. Clin Cancer Res. 2003 Nov 15;9(15):5749-55. PubMed PMID: 14654560.
4: Kouraklis G, Theocharis S. Histone deacetylase inhibitors and anticancer therapy. Curr Med Chem Anticancer Agents. 2002 Jul;2(4):477-84. Review. PubMed PMID: 12678732.
5: Daud A, Munster P, Munster P, Spriggs DR. New drugs in gynecologic cancer. Curr Treat Options Oncol. 2001 Apr;2(2):119-28. Review. PubMed PMID: 12057130.
6: Butler LM, Webb Y, Agus DB, Higgins B, Tolentino TR, Kutko MC, LaQuaglia MP, Drobnjak M, Cordon-Cardo C, Scher HI, Breslow R, Richon VM, Rifkind RA, Marks PA. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin Cancer Res. 2001 Apr;7(4):962-70. PubMed PMID: 11309347.
